Palo Alto Networks' (PANW) potential acquisition of CyberArk (CYBR) would complement Palo Alto's existing and bolster its ...

CyberArk Software ( NASDAQ: CYBR) soared 13% on a report that Palo Alto Networks ( NASDAQ: PANW) is in discussions to ...

Discover how Obexelimab's unique B-cell inhibition and pivotal Phase 3 IgG4 results could drive Zenas BioPharma, Inc.'s ...

Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma  Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction ...

Winners to be Revealed September 10 at Fierce Pharma Marketing Awards Gala in Philadelphia, During the Fierce Pharma WeekNEW YORK, July 28, ...

Vertiv (NYSE:VRT) has agreed to acquire the Great Lakes Data Racks & Cabinets family of companies for $200 million. Vicebio, ...

Thermo Fisher Scientific (TMO) recently unveiled two new electron microscopes, Scios 3 and Talos 12, at the Microscopy & Microanalysis conference, reinforcing their advanced technology offerings. The ...

Gilead Sciences (GILD) stock gains as Needham upgrades the company to Buy from Hold citing its new HIV prevention injectable, ...

With four approved indications globally, including two in the front-line setting, the approval further affirms Sarclisa as an established MM treatment option, reflecting Sanofi’s ambition to address ...

An update from BB Biotech ( ($CH:BION) ) is now available. In Q2 2025, BB Biotech outperformed the Nasdaq Biotech Index, with a 10.2% increase in ...

Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a narrow economic moat. Growth of existing products and new product launches should help offset ...